Browsing by Publisher "Verduci Editore s.r.l"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Predictive value of quantitative metabolic tumor volume and metabolic index analysis in lung cancer stereotactic radiotherapy with F-18 FDG PET/CT
    (Verduci Editore s.r.l, 2022) Aras F.; Olmezoglu A.
    OBJECTIVE: The objective of this study was to investigate predictive value of quantitative metabolic tumor volume and metabolic index analysis in lung cancer stereotactic radiotherapy with F-18 FDG PET/CT. PATIENTS AND METHODS: Overall, 94 early-stage non-small cell lung cancer (NSCLC) patients who were administered stereotactic radiotherapy were included in the study. RESULTS: Most of the study patients were male (91.5%). Mean age of the patients was 68.5 ± 9.0 years. The primary lung tumor was located centrally and peripherally in 25 (26.6%) and 69 (73.4%) of the patients, respectively. The median gross tumor volume (GTV) was 16.2 cc [interquartile range (IQR): 7.1-32.9]. Whereas all patients who had peripheral tumors survived, 17 patients with central tumors (70.8%) died during the study period (p = 0.001). Biologically effective dose (BED10) values were significantly higher in patients who had peripheral tumors compared with patients with central tumors (p = 0.001). Significantly more patients died in patients who had BED values below 100 Gy compared to patients who had BED values over 100 Gy (p = 0.001). The survival distributions for the two groups were significantly different (p < 0.001). Only GTV and Pretreatment SUVmean appeared as significant predictors of mortality. BED10 values showed a significant and strong positive correlation with total radiation dose, whereas it showed a significant strong negative correlation with number of fractions. CONCLUSIONS: The use of repeated 18F-FDG PET to assess survival early during stereotactic radiotherapy is possible in patients with early-stage non-small cell lung cancer. A decrease in GTV and pretreatment SUVmean according to F-18 FDG PET/CT uptake by the primary tumor correlates with survival. © 2022 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    The clinicopathological features and survival of Castleman disease: A multicenter Turkish study
    (Verduci Editore s.r.l, 2022) Yildiz J.; Bagci M.; Sayin S.; Kaya A.; Yilmaz F.; Ekinci O.; Dal M.S.; Basturk A.; Aydogdu I.; Albayrak M.; Dogan A.; Erkurt M.A.; Korkmaz S.; Ulas T.; Eser B.; Altuntas F.
    Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment
    (Verduci Editore s.r.l, 2023) Çakir E.; Saydan D.; Gülbagci B.; Özen M.; Uǧurlu İ.; Demirci A.; Bilir F.; Hacibekiroglu İ.; Yildiz N.; Akcali S.; Altindis M.; Varim C.; Yaylaci S.; Bilir C.
    OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immunity in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sinovac- CoronaVac COVID-19 vaccine immunogenicity and compared it with natural COVID-19 disease in cancer patients during their cancer therapy. PATIENTS AND METHODS: A total of 111 patients with cancer and who are on active treatment were included in the study. This is a single- center study and was designed prospectively. Two group of patients were included in the study, natural disease and vaccinated group. RESULTS: A total of 111 patients were included in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while after the second dose of vaccine were 2.6 (1.0- 7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immunotehrapy/ targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference between the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively]. CONCLUSIONS: The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving active systemic therapy. On the other hand, natural disease immunogenicity was higher than vaccinated group. © 2023 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission
    (Verduci Editore s.r.l, 2023) Toprak O.B.; Akpolat T.; Uzun O.; Pinar Deniz P.; Kokturk N.; Varol A.; Guzel E.; Ercelik M.; Gultekin O.; Guner R.; Turan S.; Gökbulut Bektaş Ş.; Coskun N.; Bakan N.; Nuri Yakar M.; Eren Kutsoylu O.; Ergan B.; Argun Bariş S.; Başyiğit İ.; Boyaci H.; Çetinkaya F.; Çolak H.; Aykac N.; Baran Ketencioğlu B.; Türe Yüce Z.; Akkaya Isik S.; Serap Yilmaz E.; Karaoğlanoğlu S.; Berik Safci S.; Ozkan G.; Kose N.; Kizilirmak D.; Havlucu Y.; Nural S.; Kerget F.; Sunal Ö.; Yuksel A.; Bestepe Dursun Z.; Deveci F.; Kuluozturk M.; Ataoglu O.; Dursun M.; Keskin S.; Emin Sezgin M.; Aktepe Sezgin E.N.; Eser F.; Akyildiz L.; Selim Almaz M.; Kayaaslan B.; Hasanoğlu İ.; Bayrak M.; Gümüş A.; Sağcan G.; Cuhadaroglu C.; Kucuk H.; Onyilmaz T.; Mete B.; Kilinc O.; Oya Itil B.
    OBJECTIVE: As the pandemic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to assess hospitalized patients' vaccination status and document the efficacy of boosters. PATIENTS AND METHODS: The patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 patients from collaborating centers were randomly enrolled to understand/estimate the distribution of vaccination status in hospitalized patients and to compare the efficacy of vaccination/booster protocols. RESULTS: 2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 doses, and 3.26-fold in those who received 4 doses. CONCLUSIONS: The results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disadvantaged. © 2023 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    Oxytocin mitigates peripheral nerve damage via Nrf2 and irisin pathway
    (Verduci Editore s.r.l, 2023) Tosyali H.K.; Bora E.S.; Çinaroğlu O.S.; Erbaş O.
    OBJECTIVE: Peripheral nerve injuries present challenges in achieving full functional restoration, necessitating effective therapeutic strategies. Oxytocin, known for its neuroprotective and anti-inflammatory properties, has shown potential in nerve recovery. This study aims to elucidate the role of oxytocin in nerve recovery via the nuclear factor erythroid 2-related factor 2 (Nrf2) and irisin pathways. MATERIALS AND METHODS: Adult male Wistar rats (n=30) were subjected to surgical dissection of sciatic nerves and divided into Control, Surgery and Saline Group, and Surgery and Oxytocin (OT) group. Electromyographic (EMG) recordings, inclined plane tests, and histological assessments were conducted to evaluate nerve function, and Nerve growth factor (NGF) immunoexpression and axonal parameters were measured. Plasma irisin levels, nerve NGF, and Nrf2 levels were quantified. RESULTS: The Surgery and Saline Group exhibited impaired EMG latency, amplitude, and inclined plane score compared to Controls, while the Surgery and OT Group demonstrated improved outcomes. Histomorphometric analysis revealed increased NGF immunoexpression, axon number, diameter, and reduced fibrosis in the Surgery and OT Group. Plasma irisin levels were higher following oxytocin administration. Additionally, nerve NGF and Nrf2 levels were elevated in the Surgery and OT Group. CONCLUSIONS: OT administration mitigated nerve injury effects, promoting functional and histological improvements. Elevated NGF and Nrf2 levels, along with increased irisin, indicated the potential interplay of these pathways in enhancing nerve recovery. The results align with OT’s neuroprotective and anti-inflammatory roles, suggesting its potential as a therapeutic intervention for nerve injuries. OT’s positive impact on nerve recovery is associated with its modulation of Nrf2 and irisin pathways, which collectively enhance antioxidant defense and neurotrophic support and mitigate inflammation. These findings underline OT’s potential as a therapeutic agent to enhance nerve regeneration and recovery. Further research is needed to elucidate the intricate molecular mechanisms and potential clinical applications of OT in nerve injury management. © 2023 Verduci Editore s.r.l. All rights reserved.